abs295.txt	purpose		in	this	era	of	precision-based	medicine		for	optimal	patient	care	results	reported	from	commercial	next-generation	sequencing	(ngs)	assays	shouldadequately	reflect	the	burden	of	somatic	mutations	in	the	tumor	being	sequenced	here		we	sought	to	determine	the	prevalence	of	clonal	hematopoiesis	leading	topossible	misattribution	of	tumor	mutation	calls	on	unpaired	foundation	medicinengs	assays	experimental	design		this	was	a	retrospective	cohort	study	ofindividuals	undergoing	ngs	of	solid	tumors	from	two	large	cancer	centers		weidentified	and	quantified	mutations	in	genes	known	to	be	frequently	altered	inclonal	hematopoiesis	(dnmt3a		tet2		asxl1		tp53		atm		chek2		sf3b1		cbl		jak2)that	were	returned	to	physicians	on	clinical	foundation	medicine	reports		for	asubset	of	patients		we	explored	the	frequency	of	true	clonal	hematopoiesis	bycomparing	mutations	on	foundation	medicine	reports	with	matched	bloodsequencing	results		mutations	in	genes	that	are	frequently	altered	in	clonalhematopoiesis	were	identified	in	65%	(1	139/1	757)	of	patients	undergoing	ngs	when	excluding	tp53		which	is	often	mutated	in	solid	tumors		these	events	werestill	seen	in	35%	(619/1	757)	of	patients		utilizing	paired	blood	specimens		wewere	able	to	confirm	that	8%	(18/226)	of	mutations	reported	in	these	genes	weretrue	clonal	hematopoiesis	events		the	majority	of	dnmt3a	mutations	(64%		7/11)and	minority	of	tp53	mutations	(4%		2/50)	were	clonal	hematopoiesis	conclusions	clonal	hematopoiesis	mutations	are	commonly	reported	on	unpaired	ngs	testing		itis	important	to	recognize	clonal	hematopoiesis	as	a	possible	cause	ofmisattribution	of	mutation	origin	when	applying	ngs	findings	to	a	patient's	care	clin	cancer	res		1-7		Â©2018	aacr	
